Join us at Drug Discovery, as we bring together experts in the field to explore the latest advancements and their transformative potential in disease detection. The session will delve into key breakthroughs that have enhanced the sensitivity and specificity of liquid biopsy techniques, making them a powerful tool for early diagnosis and monitoring of various diseases.
Elevating Disease Detection
Unleashing the potential of liquid biopsy with key breakthroughs and insights
Drug Target Review will host an exclusive, free-to-attend, event during the annual Drug Discovery Event this October in London, UK.
Join us, as we bring together experts in the field to explore the latest advancements and their transformative potential in disease detection. The session will delve into key breakthroughs that have enhanced the sensitivity and specificity of liquid biopsy techniques, making them a powerful tool for early diagnosis and monitoring of various diseases.
Key Topics:
Technological Innovations:
Examination of cutting-edge technologies that have improved the detection of biomarkers in samples.
Clinical Applications:
Discussion on how liquid biopsy is being integrated into clinical practice for early cancer detection, treatment monitoring, and prognosis assessment.
Challenges and Solutions:
Addressing the current limitations of liquid biopsy, along with potential solutions.
Future Directions:
Insights into ongoing research and prospects for liquid biopsy, including its role in personalized medicine and its integration with other diagnostic modalities like artificial intelligence.
Speaker:
Elad Katz
Dr Elad Katz has been developing organoid-based drug discovery in the University of Dundee. This activity has been based on his inventive technology, NaviPlate and is the basis for three commercial projects. Having trained initially in chemistry, Elad did his PhD in immunology in University of Glasgow. During his post-doc in the USA, he became interested in complex biology, through 3D cell cultures of cancer cells. Dr Katz has been passionate about bringing these systems into mainstream drug discovery to the benefit of patients with unmet clinical needs. He has been involved in two successful spin-outs in this space and is hoping to manage a third next year.